Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fampridine sustained-release - Acorda Therapeutics

Drug Profile

Fampridine sustained-release - Acorda Therapeutics

Alternative Names: 4-AP - Acorda Therapeutics; Ampyra; BIIB 041; Dalfampridine ER; Dalfampridine extended-release; Dalfampridine-SR; EL 970; Fampridine ER; Fampridine extended-release; Fampridine-PR; Fampridine-SR; Fampyra; Neurelan

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elan Drug Technologies
  • Developer Acorda Therapeutics; Biogen; John Hopkins University; Kessler Foundation; University of California at Los Angeles; University of Florida; University of Miami
  • Class Aminopyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase III Ataxia
  • Phase II Spinal cord injuries; Spinocerebellar degeneration; Transverse myelitis
  • Phase I/II Parkinson's disease
  • No development reported Cerebral palsy
  • Discontinued Neurological disorders

Most Recent Events

  • 10 Sep 2018 The US Court of Appeals for the Federal Circuit upholds District Court’s Decision to invalidate four dalfampridine patents
  • 17 Nov 2017 Acorda Therapeutics receives royalty monetisation with HealthCare Royalty Partners
  • 16 Oct 2017 Acorda Therapeutics completes a phase II trial in Spinal cord injuries in USA (PO) (NCT01621113)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top